Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
October 24, 2026

Research Will Use Lunit's AI-powered Pathology Platform to...

1500D aramid fiber meets a universe-inspired particle array,...

MARIETTA, Ga., Oct. 22, 2026 /PRNewswire/ -- Starting...

DEEp SEA is a global Phase III trial evaluating efficacy, safety and...

First FDA-approved stent designed specifically for the smallest patients with certain congenital...

Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan...

Ribbon-cutting held on World Suicide Prevention DayRED BANK, N.J., Sept. 12, 2026...






